Search Results - "Gårsjö, J."

125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab by Veenstra, C., Ellegård, S., Pérez-Tenorio, G., Fagerström, V., Gårsjö, J., Briedis, K., Sundqvist, M., Malmström, A., Wingren, S., Stål, O.

Get full text

ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2‑positive metastatic breast cancer treated with trastuzumab by Ellegård, Sander, Veenstra, Cynthia, Pérez-Tenorio, Gizeh, Fagerström, Victor, Gårsjö, Jon, Gert, Krista, Sundquist, Marie, Malmström, Annika, Wingren, Sten, Elander, Nils O, Hallbeck, Anna-Lotta, Stål, Olle

“…Trastuzumab has markedly improved the treatment and long-term prognosis of patients with HER2-positive breast cancer. A frequent clinical challenge in patients…”
Get full text

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer by Karlsson, Elin, Veenstra, Cynthia, Gårsjö, Jon, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle

“…Purpose The protein tyrosine phosphatase, non-receptor type 2 (PTNP2) regulates receptor tyrosine kinase signalling, preventing downstream activation of…”
Get full text

125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab by Veenstra, C., Ellegard, S., Perez-Tenorio, G., FagerstrOm, V., Garsjo, J., Briedis, K., Sundqvist, M., MalmstrOm, A., Wingren, S., Stai, O.

Get full text